Clinical Trial Update: Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Erlotinib (Tarceva) in patients with advanced non-small cell lung cancer who failed prior chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy | Phase 2 | Status: COMPLETED